Prospera Financial Services Inc cut its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 81.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,083 shares of the company's stock after selling 13,673 shares during the period. Prospera Financial Services Inc's holdings in Moderna were worth $206,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of MRNA. Ashton Thomas Private Wealth LLC acquired a new stake in Moderna in the 2nd quarter valued at about $26,000. Family Firm Inc. purchased a new stake in shares of Moderna in the second quarter valued at about $33,000. Bank & Trust Co acquired a new stake in shares of Moderna in the second quarter valued at approximately $36,000. Hanseatic Management Services Inc. purchased a new position in shares of Moderna during the 2nd quarter worth approximately $48,000. Finally, Plato Investment Management Ltd raised its position in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock worth $49,000 after purchasing an additional 288 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.
Moderna Stock Down 3.7 %
NASDAQ:MRNA traded down $1.61 during mid-day trading on Tuesday, reaching $42.05. The stock had a trading volume of 7,242,732 shares, compared to its average volume of 4,889,785. The stock's 50 day simple moving average is $54.45 and its two-hundred day simple moving average is $93.15. Moderna, Inc. has a 1-year low of $35.80 and a 1-year high of $170.47. The company has a market capitalization of $16.18 billion, a price-to-earnings ratio of -7.45 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.
Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period in the prior year, the company posted ($1.39) EPS. The business's revenue was up 3.8% compared to the same quarter last year. Equities analysts anticipate that Moderna, Inc. will post -9.44 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the company. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a report on Friday, November 8th. Leerink Partners dropped their price objective on Moderna from $60.00 to $48.00 and set an "underperform" rating for the company in a research report on Tuesday, September 17th. Oppenheimer lowered shares of Moderna from an "outperform" rating to a "market perform" rating in a report on Friday, September 13th. Wolfe Research started coverage on shares of Moderna in a report on Friday, November 15th. They set an "underperform" rating and a $40.00 price target for the company. Finally, Bank of America reduced their price objective on shares of Moderna from $130.00 to $110.00 and set a "neutral" rating on the stock in a research note on Friday, September 13th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $83.26.
Check Out Our Latest Stock Analysis on Moderna
Insider Transactions at Moderna
In other news, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company's stock, valued at approximately $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 2,930 shares of company stock worth $217,170. Insiders own 15.20% of the company's stock.
Moderna Company Profile
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
